Kleinberg DL Noel GL Frantz AG.

Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.

N Engl J Med. 296: 589-600Freeman ME Kanyicska B Lerant A Nagy G.

Prolactin: structure, function, and regulation of secretion.

Physiol Rev. 80: 1523-1631Martinez de la Escalera G Weiner RI.

Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion.

Endocr Rev. 13: 241-255

Excitatory neuromodulator reduces dopamine release, enhancing prolactin secretion.

Neuron. 65: 147-149Morel GR Caron RW Console GM et al.

Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage.

Brain Res Bull. 80: 347-352DeMaria JE Livingstone JD Freeman ME.

Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons.

Brain Res. 879: 139-147Livingstone JD Lerant A Freeman ME.

Ovarian steroids modulate responsiveness to dopamine and expression of G-proteins in lactotropes.

Neuroendocrinology. 68: 172-179

Pituitary disorders during pregnancy.

Endocrinol Metab Clin North Am. 35 (): 99-116Salvador J Dieguez C Scanlon MF.

The circadian rhythms of thyrotrophin and prolactin secretion.

Chronobiol Int. 5: 85-93Hou SH Grossman S Molitch ME.

Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis.

Am J Kidney Dis. 6: 245-249Travaglini P Moriondo P Togni E et al.

Effect of oral zinc administration on prolactin and thymulin circulating levels in patients with chronic renal failure.

J Clin Endocrinol Metab. 68: 186-190Sievertsen GD Lim VS Nakawatase C Frohman LA.

Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure.

J Clin Endocrinol Metab. 50: 846-852Hagen C Olgaard K McNeilly AS Fisher R.

Prolactin and the pituitary-gonadal axis in male uraemic patients on regular dialysis.

Acta Endocrinol. 82: 29-38Fugl-Meyer KS Nilsson M Hylander B Lehtihet M.

Sexual function and testosterone level in men with conservatively treated chronic kidney disease.

Am J Mens Health. 11: 1069-1076Lo JC Beck GJ Kaysen GA et al.

Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis.

Hemodial Int. 21: 190-196Ramirez G O'Neill Jr, WM Bloomer HA Jubiz W

Abnormalities in the regulation of prolactin in patients with chronic renal failure.

J Clin Endocrinol Metab. 45: 658-661Arnaout MA Hamzeh YS Ajlouni KM.

Prolactin responses to vasoactive intestinal polypeptide and thyrotropin releasing hormone in chronic renal failure.

Acta Endocrinol. 125: 651-656Leroith D Danovitz G Trestan S Spitz IM.

Dissociation of prolactin response to thyrotropin-releasing hormone and metoclopramide in chronic renal failure.

J Clin Endocrinol Metab. 49: 815-817Olgaard K Hagen C McNeilly AS.

Pituitary hormones in women with chronic renal failure: the effect of chronic intermittent haemo- and peritoneal dialysis.

Acta Endocrinol. 80: 237-246Saha MT Saha HH Niskanen LK Salmela KT Pasternack AI.

Time course of serum prolactin and sex hormones following successful renal transplantation.

Nephron. 92: 735-737Eckersten D Giwercman A Pihlsgard M Bruun L Christensson A.

Impact of kidney transplantation on reproductive hormone levels in males: a longitudinal study.

Nephron. 138: 192-201

Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition.

Clin Endocrinol (Oxf). 51: 119-126Smith TP Kavanagh L Healy ML McKenna TJ.

Technology insight: measuring prolactin in clinical samples.

Nat Clin Pract Endocrinol Metab. 3: 279-289Mooradian AD Morley JE Korchik WP Ma KW Hartfel MA Parsons JA.

Comparison between bioactivity and immunoreactivity of serum prolactin in uraemia.

Clin Endocrinol (Oxf). 22: 241-247Rodriguez-Puyol D Martin-Oar JE Cachofeiro MV del Pino D Lopez-Novoa JM Hernando L

Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients.

J Clin Endocrinol Metab. 62: 352-356Yavuz D Topcu G Ozener C Akalin S Sirikci O.

Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy.

Clin Endocrinol (Oxf). 63: 520-524Sari F Sari R Ozdem S Sarikaya M Cetinkaya R.

Serum prolactin and macroprolactin levels in diabetic nephropathy.

Clin Nephrol. 78: 33-39

Evaluation and management of galactorrhea.

Am Fam Physician. 85: 1073-1080

Benign breast disorders.

N Engl J Med. 353: 275-285Vaidyanathan L Barnard K Elnicki DM.

Benign breast disease: when to treat, when to reassure, when to refer.

Cleve Clin J Med. 69: 425-432Dhindsa S Reddy A Karam JS et al.

Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease.

Eur J Endocrinol. 173: 359-366Pertuz W Castaneda DA Rincon O Lozano E.

Sexual dysfunction in patients with chronic renal disease: does it improve with renal transplantation?.

Transplant Proc. 46: 3021-3026Carrero JJ Kyriazis J Sonmez A et al.

Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events andmortality in patients with CKD.

Clin J Am Soc Nephrol. 7: 207-215Muir JW Besser GM Edwards CR et al.

Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis.

Clin Nephrol. 20: 308-314Vircburger MI Prelevic GM Peric LA Knezevic J Djukanovic L.

Testosterone levels after bromocriptine treatment in patients undergoing long-term hemodialysis.

J Androl. 6: 113-116Peces R Horcajada C Lopez-Novoa JM Frutos MA Casado S Hernando L.

Hyperprolactinemia in chronic renal failure: impaired responsiveness to stimulation and suppression. Normalization after transplantation.

Nephron. 28: 11-16

Drugs and prolactin.

Pituitary. 11: 209-218

Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.

Eur J Endocrinol. 161: 163-169

Diagnosis and management of galactorrhea.

Am Fam Physician. 70: 543-550Oguz Y Oktenli C Ozata M et al.

The midnight-to-morning urinary cortisol increment method is not reliable for the assessment of hypothalamic-pituitary-adrenal insufficiency in patients with end-stage kidney disease.

J Endocrinol Invest. 26: 609-615Stroud A Dhaliwal P Alvarado R et al.

Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis.

Pituitary. 23: 595-609Ramirez G Gomez-Sanchez C Meikle WA Jubiz W.

Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis.

Arch Intern Med. 142: 1448-1452Wallace EZ Rosman P Toshav N Sacerdote A Balthazar A.

Pituitary-adrenocortical function in chronic renal failure: studies of episodic secretion of cortisol and dexamethasone suppressibility.

J Clin Endocrinol Metab. 50: 46-51McDonald WJ Golper TA Mass RD et al.

Adrenocorticotropin-cortisol axis abnormalities in hemodialysis patients.

J Clin Endocrinol Metab. 48: 92-95

Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease.

Endocr Connect. 2: 23-31Russcher M Chaves I Lech K et al.

An observational study on disturbed peripheral circadian rhythms in hemodialysis patients.

Chronobiol Int. 32: 848-857Albiston AL Obeyesekere VR Smith RE Krozowski ZS.

Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme.

Mol Cell Endocrinol. 105: R11-R17Mongia A Vecker R George M et al.

Role of 11betaHSD type 2 enzyme activity in essential hypertension and children with chronic kidney disease (CKD).

J Clin Endocrinol Metab. 97: 3622-3629Homma M Tanaka A Hino K et al.

Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.

Metabolism. 50: 801-804Kawai S Ichikawa Y Homma M.

Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure.

J Clin Endocrinol Metab. 60: 848-854Crowley RK Argese N Tomlinson JW Stewart PM.

Central hypoadrenalism.

J Clin Endocrinol Metab. 99: 4027-4036Sakao Y Sugiura T Tsuji T et al.

Clinical manifestation of hypercalcemia caused by adrenal insufficiency in hemodialysis patients: a case-series study.

Intern Med. 53: 1485-1490Clodi M Riedl M Schmaldienst S et al.

Adrenal function in patients with chronic renal failure.

Am J Kidney Dis. 32: 52-55Soule S Van Zyl Smit C Parolis G et al.

The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism.

Clin Endocrinol (Oxf). 53: 221-227Charmandari E Nicolaides NC Chrousos GP.

Adrenal insufficiency.

Lancet. 383: 2152-2167Schmidt IL Lahner H Mann K Petersenn S.

Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.

J Clin Endocrinol Metab. 88: 4193-4198Ramirez G Bittle PA Sanders H Rabb HA Bercu BB.

The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin.

J Clin Endocrinol Metab. 78: 63-69Siamopoulos KC Dardamanis M Kyriaki D Pappas M Sferopoulos G Alevisou V.

Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients.

Perit Dial Int. 10: 153-156Bancos I Hahner S Tomlinson J Arlt W.

Diagnosis and management of adrenal insufficiency.

Lancet Diabetes Endocrinol. 3: 216-226Nieman LK Biller BM Findling JW et al.

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

J Clin Endocrinol Metab. 93: 1526-1540

The adrenal cortex.

in: Kronenberg HM Melmed S Polonsky KS Larsen PR Williams textbook of endocrinology. 11th ed. Saunders Elsevier, Philadelphia, PA ()Cardoso EM Arregger AL Budd D Zucchini AE Contreras LN.

Dynamics of salivary cortisol in chronic kidney disease patients at stages 1 through 4.

Clin Endocrinol (Oxf). 85: 313-319Workman RJ Vaughn WK Stone WJ.

Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis.

J Clin Endocrinol Metab. 63: 741-746Rosman PM Farag A Peckham R et al.

Pituitary-adrenocortical function in chronic renal failure: blunted suppression and early escape of plasma cortisol levels after intravenous dexamethasone.

J Clin Endocrinol Metab. 54: 528-533

Differential diagnosis and imaging in Cushing's syndrome.

Endocrinol Metab Clin North Am. 34 (): 403-421Chan KC Lit LC Law EL et al.

Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment.

Clin Chem. 50: 757-759Issa BG Page MD Read G John R Douglas-Jones A Scanlon MF

Undetectable urinary free cortisol concentrations in a case of Cushing's disease.

Eur J Endocrinol. 140: 148-151

Current approaches to the pharmacological management of Cushing's disease.

Mol Cell Endocrinol. 408: 185-189Nieman LK Biller BM Findling JW et al.

Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

J Clin Endocrinol Metab. 100: 2807-2831Katznelson L Laws Jr, ER Melmed S et al.

Acromegaly: an endocrine society clinical practice guideline.

J Clin Endocrinol Metab. 99: 3933-3951Kamenicky P Mazziotti G Lombes M Giustina A Chanson P.

Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.

Endocr Rev. 35: 234-281Wright AD Lowy C Fraser TR Spitz IM Rubenstein AH Bersohn I.

Serum-growth hormone and glucose intolerance in renal failure.

Lancet. 2: 798-801Mussig K Gallwitz B Ranke MB Horger M Haring HU Quabbe HJ.

Acromegaly and end-stage renal disease: a diagnostic challenge.

J Endocrinol Invest. 29: 745-749Syro LV Sundsbak JL Scheithauer BW et al.

Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation.

Pituitary. 15: 342-349Dullaart RP Meijer S Marbach P Sluiter WJ.

Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients.

Eur J Clin Invest. 22: 494-502

Pasireotide for a patient with acromegaly and chronic kidney disease on hemodialysis.

AACE Clin Case Rep. 5: e104-e107Juul KV Bichet DG Nielsen S Norgaard JP.

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.

Am J Physiol Renal Physiol. 306 ()Iitake K Kimura T Matsui K et al.

Effect of haemodialysis on plasma ADH levels, plasma renin activity and plasma aldosterone levels in patients with end-stage renal disease.

Acta Endocrinol. 110: 207-213Argent NB Wilkinson R Baylis PH.

Metabolic clearance rate of arginine vasopressin in severe chronic renal failure.

Clin Sci (Lond). 83: 583-587Shimamoto K Watarai I Miyahara M.

A study of plasma vasopressin in patients undergoing chronic hemodialysis.

J Clin Endocrinol Metab. 45: 714-720Ettema EM Zittema D Kuipers J et al.

Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and meta-analysis.

Am J Nephrol. 39: 100-109Roussel R Fezeu L Marre M et al.

Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease.

J Clin Endocrinol Metab. 99: 4656-4663Mueller T Gegenhuber A Kronabethleitner G Leitner I Haltmayer M Dieplinger B.

Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session.

Clin Biochem. 48: 1163-1166Teitelbaum I McGuinness S.

Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.

J Clin Invest. 96: 378-385Rosansky SJ Rhinehart R Shade R.

Effect of osmolar changes on plasma arginine vasopressin (PAVP) in dialysis patients.

Clin Nephrol. 35: 158-164

Endogenous and exogenous vasopressin during hemodialysis.

Semin Dial. 22: 472-475van der Zee S Thompson A Zimmerman R et al.

Vasopressin administration facilitates fluid removal during hemodialysis.

Kidney Int. 71: 318-324Tannen RL Regal EM Dunn MJ Schrier RW.

Vasopressin-resistant hyposthenuria in advanced chronic renal disease.

N Engl J Med. 280: 1135-1141Kim KM Kim SM Lee J Lee SY Kwon SK Kim HY.

Newly developed central diabetes insipidus following kidney transplantation: a case report.

Transplant Proc. 45: 2804-2806

Unmasking of undiagnosed pre-existing central diabetes insipidus after renal transplantation.

Pituitary. 15: 106-109

Clinical practice. The syndrome of inappropriate antidiuresis.

N Engl J Med. 356: 2064-2072

Significance of hypo- and hypernatremia in chronic kidney disease.

Nephrol Dial Transplant. 27: 891-898

Vasopressin: a novel target for the prevention and retardation of kidney disease?.

Nat Rev Nephrol. 9: 223-239Ho TA Godefroid N Gruzon D et al.

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.

Kidney Int. 82: 1121-1129Boertien WE Meijer E Li J et al.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Am J Kidney Dis. 61: 420-429Nakajima A Lu Y Kawano H Horie S Muto S.

Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).

Clin Exp Nephrol. 19: 1199-1205Chebib FT Sussman CR Wang X Harris PC Torres VE.

Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Nat Rev Nephrol. 11: 451-464

Vasopressin antagonists in polycystic kidney disease.

Kidney Int. 68: 2405-2418Torres VE Chapman AB Devuyst O et al.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

N Engl J Med. 367: 2407-2418